Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 August 2020 | Story Andre Damons | Photo Pierce van Heerden
Prof Felicity Burt is a passionate virologist with more than 25 years of research on medically significant viruses that cycle in nature and are transmitted to humans via mosquitoes, ticks, or animals.

Prof Felicity Burt, an expert in arbovirology in the Division of Virology, has been leading the University of the Free State (UFS) COVID-19 Task Team over the past five months. Prof Burt is a passionate virologist with more than 25 years of research on medically significant viruses that cycle in nature and are transmitted to humans via mosquitoes, ticks, or animals.

As the UFS is celebrating its champion women this Women’s Month, Prof Burt gives us some insight into who she is. 

Please tell us about yourself

I am an arbovirologist from the Division of Virology in the Faculty of Health Sciences, and the National Health Laboratory Service. Who am I? I am a mum, a wife, a daughter, a sister, a sister-in-law, a friend, a scientist, a colleague, a professor.  I am passionate about my work and have spent more than 25 years researching medically significant viruses that cycle in nature and are transmitted to humans via mosquitoes, ticks, or animals. 
My research group investigates the various mechanisms that viruses use to cause disease, and I am particularly interested in how our bodies respond to infection that can help us develop vaccines or therapies. Raising awareness of these viruses, profiling disease associated with different viruses, and developing tools for surveillance programmes all contribute towards understanding pathogens and the public-health implications. I am so grateful for the opportunities my career has provided me, which includes travelling all over the world for conferences and meetings and participating in outbreak responses in Africa.   
   
Is there a woman who inspires you and who you would like to celebrate this Women’s Month, and why?

I am inspired by all women who set goals and work to achieve them. The goals may vary, but they are important and challenging to each individual.  Hence, I would like us to acknowledge and celebrate all women who achieve their goals through hard work, dedication, and of course, plenty of passion. 

What are some of the challenges you’ve faced in your life that have made you a better woman?

I have always been quite a shy person and still find it challenging to stand up in front of an audience. I was born in Zimbabwe and when I finished school, I moved to South Africa to study at the University of the Witwatersrand. Moving on my own to Johannesburg at the age of 18 was definitely a challenge for a quiet, reserved girl from Harare. Compared to home, Johannesburg was a mammoth city; however, I absolutely loved university life, met people who became lifelong friends, and pursued a career in science. I try to learn from my many mistakes and treat others how I would like to be treated, especially with kindness. 

What advice would you give to the 15-year-old you?

Dream on girl, and it doesn’t matter if they don’t all come true; life isn’t going to turn out as expected, but as long as you enjoy the journey. You don’t have to be the best, but you have to do your best – with passion of course. 

What would you say makes you a champion woman [of the UFS]?

To be honest, I wouldn’t call myself a champion, but I am quite proud of what I have established at the UFS. With hard work and passion, contributions from colleagues, support from management, and never forgetting a whole bunch of wonderfully enthusiastic students, we have built an active postgraduate research group, graduated multiple students, published scientific articles in international journals, presented our research at conferences, contributed to community engagement, had fun, and still have plenty more to achieve!  

 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept